Tiziana Life Sciences announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes, T1D. "With the FDA approval of the humanized anti-CD3 mAb TZIELD and then its subsequent announced acquisition of Provention Bio by Sanofi for $2.9 billion, CD3 has emerged as an established and attractive target for Type 1 Diabetes," commented Gabriele Cerrone, Executive Chairman, Founder and interim Chief Executive Officer of Tiziana. "We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TLSA:
- Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
- Tiziana to develop intranasal foralumab for the treatment of long COVID
- Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
- Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
- Tiziana Life Sciences announces data on intranasal anti-CD3 monoclonal antibody